Format

Send to

Choose Destination
J Exp Clin Cancer Res. 2011 Jan 21;30:12. doi: 10.1186/1756-9966-30-12.

The immunoregulatory mechanisms of carcinoma for its survival and development.

Author information

1
Department of Urologic Sciences, University of British Columbia, Vancouver, Canada. caigan@interchange.ubc.ca

Abstract

The immune system in patients detects and eliminates tumor cells, but tumors still progress persistently. The mechanisms by which tumor cells survive under the pressure of immune surveillance are not fully understood. This review is to present the evidence from clinical studies, showing a significant correlation of clinicopathological features of carcinoma with: (1) the loss of classical human leukocyte antigen class I, (2) the up-regulation of non-classical human leukocyte antigen class I, pro-apoptotic Fas ligand and receptor-binding cancer antigen expressed on SiSo cells I, and (3) the formation of immunosuppressive microenvironment by up-regulation of transforming growth factor-beta, Galectin-1, inhibitory ligand B7s, indoleamine 2,3-dioxygenase and arginase, as well as by recruitment of tumor-induced myeloid-derived suppressor cells and regulatory T cells. All of these factors may together protect carcinoma cells from the immune-cytotoxicity.

PMID:
21255410
PMCID:
PMC3031251
DOI:
10.1186/1756-9966-30-12
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center